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SUMMARY Omenn syndrome is a variant of combined severe immunodeficiency 
due to mutations in RAG genes. It is characterized by polymorph symptoms and 
lethal outcome. We report on two cases of Omenn syndrome. Infants were aged 50 
and 46 days. The clinical and biological signs were typical and complete in the first 
case. In the second case, only the cutaneous signs were present. Diagnosis was con-
firmed by genetic study. The Rag1 T631 mutation was found in these two patients. 
Hematopoietic stem cell transplantation could not be done and the evolution was 
fatal in both cases because of severe infectious episodes. Prenatal diagnosis was 
performed in the two families and each family has currently a healthy child. In con-
clusion, early diagnosis of Omenn syndrome may avoid infectious complications 
responsible for delay in therapeutic management. Genetic study confirms the di-
agnosis. The treatment usually consists of hematopoietic stem cell transplantation 
in association with immunosuppressive drugs. Prenatal diagnosis is very important 
to allow parents to have healthy children.
KeY wORdS: Omenn syndrome, severe combined immunodeficiency, bone mar-
row transplantation, RAG mutations
INTROdUCTION
Omenn syndrome (OS) is an autosomal recessive 
combined immunodeficiency (1). It is characterized 
by a diffuse erythematous scaly rash, recurrent severe 
infections, protracted diarrhea, lymphadenopathy, 
hepatosplenomegaly, lymphocytosis, eosinophilia 
and lymphocytic infiltration in the skin, gut, liver, and 
spleen (2). Immune defects are very diverse including 
different degrees of eosinophilia and IgE levels, hy-
pogammaglobulinemia with B cell deficiency, thymic 
hypoplasia and reduced proliferative responses to 
mitogens (3-5). We report on two cases of OS occur-
ring in infants aged 50 and 46 days. 
CASe 1
A. D. was a 50-day-old male infant when admitted 
to the hospital. He was the first child to first-degree 
consanguineous parents. There was no family history 
of early death or immunodeficiency. The pregnancy 
and delivery were uneventful with birth weight of 
4 kg. A few days after birth, he developed therapy-
resistant dermatitis with generalized desquamative 
eruption and alopecia (Figs. 1 and 2). The parents 
brought the child for consultation to our department, 
when huge axillary lymphadenopathy appeared after 
BCG vaccination. Physical examination revealed no 
fever, weight 4100 g, height 56.5 cm, oral mucosal 
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candidiasis, diffuse and erythematous dermatitis with 
fistulized scalp abscess, alopecia, feet edema, lymph-
adenopathy and splenomegaly. Laboratory investi-
gations revealed anemia (7.8 g/dL), leukocytosis (34 
000/mm3), lymphocytosis (20 400/mm3), eosinophilia 
(1670/mm3), low serum protein (33 g/L), and low 
gammaglobulins (0.3 g/L) with high IgE (134 UI/L). 
Chest x-ray was normal, thymus was present. Trans-
fontanellar brain and abdominal ultrasounds were 
also normal. Blood and abscess culture grew Staphy-
lococcus aureus. The infant was isolated, treated with 
oxacillin and fluconazole, and transfused with irradi-
ated blood.
Immunologic evaluation showed no humoral re-
sponse immunity, abnormal cellular response immu-
nity, abnormal response to mitogens and no response 
to antigens. OS was suspected. The infant received 
intravenous immunoglobulins. HLA typing showed 
compatibility between the patient and his father. The 
child was then scheduled for bone marrow transplan-
tation. Molecular analysis revealed homozygous Rag1 
Del T631 mutation. Unfortunately, the patient died 
from severe sepsis before marrow transplantation at 
the age of 93 days. Prenatal diagnosis was performed 
and the parents now have a healthy 2-year-old girl.
CASe 2
E. C. was a 46-day-old female infant when admit-
ted to the hospital. She was the first child to consan-
guineous parents with no particular family history. 
At birth, she weighed 3400 g and presented diffuse 
erythroderma. She was BCG vaccinated at birth with 
no complications. From the first week of age, she 
developed recurrent otitis, bronchitis and gastroen-
teritis. She was admitted to the hospital at the age of 
46 days to manage a failure to thrive. Clinical exami-
nation showed weight of 3 kg, diffuse ichthyosiform 
erythroderma, alopecia and absent eyebrows (Fig. 3). 
Blood cell count revealed microcytic hypochromic 
anemia (7.2 g/dL), leukocytosis (15 000/mm3) with 
lymphocytes (4400/mm3) and normal eosinophil rate. 
Weight gain was initially favorable with enteral nutri-
tion. However, during hospitalization, she developed 
two episodes of severe sepsis treated with antibiot-
ics. Control biologic parameters revealed leukocyto-
sis (57 000/mm3) with lymphocytosis (34 000/mm3) 
and moderate eosinophilia (750/mm3). Chest x-ray 
showed absence of thymic shadow. Protein electro-
phoresis revealed a low serum protein concentration 
(38 g/L) and agammaglobulinemia.
The study of cell mediated immunity revealed 
complete absence of B lymphocytes with normal 
number of T lymphocytes. The latter showed normal 
response to phytohemagglutinins and anti CD3, but 
no response to tuberculin. The diagnosis of OS was 
established and the infant was treated with cotrimox-
azole, itraconazole and gammaglobulin infusions. 
Genetic study revealed homozygous Rag1 Del T631 
mutation. The infant was scheduled for bone mar-
row transplantation, but she died at the age of four 
months from severe pneumonia. Prenatal diagnosis 
was performed and the parents now have a healthy 
3-year-old girl and the mother is pregnant with a 
healthy fetus.
dISCUSSION
In 1965, Omenn described 12 infants in whom the 
major features were the onset of severe skin eruption 
followed by hepatosplenomegaly, lymphadenopa-
thy, hypogammaglobulinemia, and eosinophilia in 
the first month of age (6). Failure to thrive and recur-
rent febrile illnesses progressed to a fatal outcome 
within six months in all cases. In our first patient, 
clinical findings were all typical of OS, whereas in our 
second patient only cutaneous manifestations were 
present and biologic findings were important to re-
veal the diagnosis.
The gradual onset of severe dermatitis, lymph-
adenopathy and hepatosplenomegaly as well as eo-
sinophilia during the first and second month of life 
suggest that antigenic stimulation may play a central 
role in the clinical and immune manifestations of 
this disease. In our patients, immunological investi-
gations showed severe immunodeficiency. Serum 
immunoglobulins were very low except for the IgE 
level, which was high in the first case. Lymphocyte 
proliferative response to mitogens was markedly 
depressed despite the presence of a normal number 
of T lymphocytes and their subsets. This is due to an 
intrinsic defect of their activation after antigen or 
Figure 1. Generalized exfoliative dermatitis and ab-
sent eyebrows.
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mitogen stimulation. This can be seen in combined 
immunodeficiency patients as well as in other syn-
dromes such as ataxia-telangiectasia and DiGeorge 
syndrome (7). OS is differentiated from severe com-
bined immunodeficiency by additional autoimmu-
nity and atopy (erythroderma, eosinophilia and high 
IgE level), which signify substantial immune dysregu-
lation (8). OS is associated with a severe disturbance 
in both T- and B-cell development. 
The best-characterized defects leading to OS are 
homozygous or compound heterozygous mutations 
in either recombinase-activating gene (RAG) 1 or 2, 
which encode RAG1 and RAG2 enzymes. Normally, 
RAG1 and RAG2 enzymes, which are restricted to 
immature lymphocytes, initiate a V(D)J (Variable, 
Diversity, Joining) recombination that leads to both 
T- and B-cell development. In fact, OS is caused by hy-
pomorphic mutations in RAG that impair but do not 
abolish the process of VDJ recombination and may 
differentially impact on VDJ recombination activity 
and hence lead to a variable ability to sustain T and B 
cell lymphopoiesis. It is characterized by the presence 
of only a small number of T cell clones, which infil-
trate the skin, gut, liver, and spleen leading to clinical 
manifestations. The number of peripheral blood lym-
phocytes can be decreased, normal, or increased with 
variable B cell counts and hypogammaglobulinemia 
(9,10).
Mutations in RAG1 or RAG 2 are found in most OS 
patients (11), as seen in our patients. However, other 
mutations have been reported, such as IL7RA gene, 
ARTEMIS, and RNA component of RNase mitochon-
drial RNA processing and DNA ligase IV mutations 
(12-17). The study by Wada et al. suggests that RAG 
mutation may be a genetic abnormality unique to 
OS and that all other mutations are associated with 
a variation of OS or related disorders representing a 
different type of immunodeficiency (18). 
The prognosis of patients with OS has been im-
proved since hematopoietic stem cell transplantation 
(SCT) has been introduced, although the rate of com-
plications is high because of poor clinical status, mal-
nutrition and infection prior to SCT in most patients 
(3). Immunosuppressive therapy has been used to 
control activation of auto reactive T lymphocytes us-
ing cyclosporin A alone or in association with topical 
or systemic steroids or using interferon γ in associa-
tion with anti-infectious prophylaxis to improve the 
clinical signs while waiting for allogeneic SCT (19). Us-
ing tacrolimus has little effect in improving the symp-
toms (20). Therapeutic options include bone marrow 
transplantation or more recently cord blood stem cell 
transplantation; however, the mortality is still 46%. 
Early diagnosis of OS is very important to initiate ap-
propriate treatment because life threatening infec-
tions can occur when bone marrow transplantation 
is delayed (2,21).
CONCLUSION
Severe erythroderma and alopecia are early and 
constant symptoms in OS. These clinical findings must 
indicate immunologic investigations in order to con-
firm this diagnosis. Early diagnosis may avoid failure 
to thrive and infectious complications responsible for 
delay in therapeutic management. Genetic study can 
differentiate between OS and different types of im-
munodeficiency and allow for prenatal diagnosis. OS 
is usually treated with hematopoietic stem cell trans-
plantation along with immunosuppressive drugs. 
Cord blood transplantation is a successful therapeu-
tic option in patients without a suitable donor. 
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Figure 2. Alopecia associated with generalized exfo-
liative dermatitis.
Figure 3. Alopecia and absent eyebrows.
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